These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24338265)

  • 1. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial.
    Diaby V; Adunlin G; Montero AJ
    Pharmacoeconomics; 2014 Feb; 32(2):101-8. PubMed ID: 24338265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients.
    Diaby V; Ali AA; Adunlin G; Kohn CG; Montero AJ
    Curr Med Res Opin; 2016 Jun; 32(6):991-6. PubMed ID: 26824145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis.
    Djalalov S; Beca J; Ewara EM; Hoch JS
    Pharmacoeconomics; 2019 Dec; 37(12):1525-1536. PubMed ID: 31571137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.
    Gibson EJ; Begum N; Koblbauer I; Dranitsaris G; Liew D; McEwan P; Yuan Y; Juarez-Garcia A; Tyas D; Pritchard C
    J Med Econ; 2019 Jun; 22(6):531-544. PubMed ID: 30638416
    [No Abstract]   [Full Text] [Related]  

  • 5. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves.
    Liu N; Zhou Y; Lee JJ
    BMC Med Res Methodol; 2021 Jun; 21(1):111. PubMed ID: 34074267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models.
    Gao L; Li SC
    Appl Health Econ Health Policy; 2019 Jun; 17(3):371-380. PubMed ID: 30535675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial.
    Diaby V; Adunlin G; Ali AA; Tawk R
    Breast Cancer Res Treat; 2014 Aug; 146(3):669-73. PubMed ID: 25017612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
    Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
    Montero AJ; Avancha K; Glück S; Lopes G
    Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 13. A review and comparison of methods for recreating individual patient data from published Kaplan-Meier survival curves for economic evaluations: a simulation study.
    Wan X; Peng L; Li Y
    PLoS One; 2015; 10(3):e0121353. PubMed ID: 25803659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling.
    Williams C; Lewsey JD; Mackay DF; Briggs AH
    Med Decis Making; 2017 May; 37(4):427-439. PubMed ID: 27698003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
    Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.
    Dedes KJ; Matter-Walstra K; Schwenkglenks M; Pestalozzi BC; Fink D; Brauchli P; Szucs TD
    Eur J Cancer; 2009 May; 45(8):1397-406. PubMed ID: 19147344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.
    Gibson E; Koblbauer I; Begum N; Dranitsaris G; Liew D; McEwan P; Tahami Monfared AA; Yuan Y; Juarez-Garcia A; Tyas D; Lees M
    Pharmacoeconomics; 2017 Dec; 35(12):1257-1270. PubMed ID: 28866758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [BOLERO -- another remarkable step in treatment of breast cancer].
    Rubovszky G; Láng I
    Magy Onkol; 2014 Jun; 58(2):128-32. PubMed ID: 25010761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group.
    Everest L; Blommaert S; Tu D; Pater JL; Hay A; Cheung MC; Chan KKW
    Value Health; 2022 Jul; 25(7):1157-1164. PubMed ID: 35779942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.